Cytogenetics and De Novo/Secondary AML but Not Age Are the Main Determinants for CR Rate and Hematological Recovery in Acute Myeloid Leukemia (AML) Using Intermediate Doses of Cytarabine (AraC) Delivered at the Presumptive Saturating Infusion Rate.

Autor: Becker, Cornelia *, Ali, Haifa Al *, Krahl, Rainer *, Poenisch, Wolfram *, Hasenclever, Dirk *, Mantovani, Luisa *, Freund, Mathias, Subert, R. *, Hegenbart, Ute *, Wedding, Ulrich *, Meran, Johannes *, Herold, Michael *, Peter, Norma *, Knauf, W. *, Kettner, Erika *, Ittel, T. *, Franke, Astrid *, Dachselt, K. *, Wolf, H.H. *, Kreibich, Ute *, Schulze, Manfred *, Assmann, Michael *, Grobe, Norbert *, Huhn, Renate *, Zschuppe, Ernst *, Schirmer, Veronika *, Haak, U. *, Klinkenstein, C. *, Opitz, B. *, Pasold, Rita *, Fiedler, F. *, Winkelmann, C. *, Helbig, Werner *, Niederwieser, Dietger
Zdroj: In Blood 16 November 2005 106(11):1851-1851
Databáze: ScienceDirect